Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Crosses Below 200 Day Moving Average of $7.47

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $7.47 and traded as low as $4.57. Eagle Pharmaceuticals shares last traded at $4.69, with a volume of 161,336 shares changing hands.

Eagle Pharmaceuticals Stock Performance

The company has a fifty day moving average of $5.54 and a two-hundred day moving average of $7.37. The company has a market cap of $58.20 million, a PE ratio of 3.80 and a beta of 0.41.

Institutional Trading of Eagle Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of EGRX. MetLife Investment Management LLC raised its holdings in Eagle Pharmaceuticals by 55.7% during the 1st quarter. MetLife Investment Management LLC now owns 7,765 shares of the specialty pharmaceutical company’s stock valued at $384,000 after buying an additional 2,777 shares during the period. Rhumbline Advisers grew its position in Eagle Pharmaceuticals by 2.8% in the 1st quarter. Rhumbline Advisers now owns 33,027 shares of the specialty pharmaceutical company’s stock valued at $1,635,000 after acquiring an additional 885 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Eagle Pharmaceuticals by 14.1% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,797 shares of the specialty pharmaceutical company’s stock valued at $485,000 after acquiring an additional 1,208 shares during the last quarter. BlackRock Inc. grew its position in Eagle Pharmaceuticals by 0.7% in the 1st quarter. BlackRock Inc. now owns 1,982,333 shares of the specialty pharmaceutical company’s stock valued at $98,105,000 after acquiring an additional 13,517 shares during the last quarter. Finally, Great West Life Assurance Co. Can grew its position in Eagle Pharmaceuticals by 7.2% in the 1st quarter. Great West Life Assurance Co. Can now owns 10,180 shares of the specialty pharmaceutical company’s stock valued at $517,000 after acquiring an additional 686 shares during the last quarter. Hedge funds and other institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.